A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 557-561

  Dent, Susan F ^a   Gertler, Stan ^a   Verma, Shailendra ^a   Segal, Roanne ^a   Young, Vince ^a   Goel, Rakesh ^a   Keller, Oliver ^a   Canil, Christina ^a   Iscoe, Neill ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Gemcitabine; Metastatic breast cancer; Pemetrexed; Phase II clinical trial

Indexed keywords

DEXAMETHASONE; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERIAL ISCHEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ISCHEMIA; LUNG INFILTRATE; METASTASIS; PERIPHERAL ISCHEMIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FATIGUE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PNEUMONIA; TREATMENT OUTCOME;

EID: 75549083520     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1064-z     Document Type: Article

References (18)

1. Canadian Cancer Statistics (2007) Canadian Cancer Society/National Cancer Institute of Canada
2. GB Grindey C Shih CJ Barnett, et al. 1992 LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS) Proc Am Assoc Cancer Res 33 411 (Abstract 2451)
3. C Shih GB Grindey CJ Barnett, et al. 1992 Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514 Proc Am Assoc Cancer Res 33 411 (Abstract 2452)
4. C Shih L Gosset S Gates, et al. 1996 LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition Ann Oncol 7 Suppl 1 85 (Abstract 289)
5. JA O'Shaughnessy RS Clark JL Blum, et al. 2005 Phase II study of pemetrexed in patients pretreated with an Anthracycline, Taxane, and Capecitabine for advanced breast cancer Clin Breast Cancer 6 143 149 10.3816/CBC.2005.n.016 16001992
6. DW Miles IE Smith RE Coleman AH Calvert MJ Lind 2001 A phase II study of Pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer Eur J Cancer 37 1366 1371 10.1016/S0959-8049(01)00117-4 1:CAS:528:DC%2BD3MXkvVeisbs%3D 11435066 (Pubitemid 32588747)
7. S Dent H Messersmith M Trudeau 2008 Gemcitabine in the management of metastatic breast cancer: a systematic review Breast Cancer Res Treat 108 319 331 10.1007/s10549-007-9610-z 1:CAS:528:DC%2BD1cXjsFGisLc%3D 17530427
8. JL Tonkinson JF Worzalla CH Teng, et al. 1999 Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumour activity of Gemcitabine in HT29 colon carcinoma Cancer Res 59 3671 3676 1:CAS:528:DyaK1MXltFCgu7g%3D 10446980
9. D Rauchwerger P Firby D Hedley M Moore 2000 Equilibrative-sensitive nucleotide transporter and its role in Gemcitabine sensitivity Cancer Res 60 6075 6079 1:CAS:528:DC%2BD3cXotV2lsLg%3D 11085530
10. E Giovanetti V Mey R Danesi I Mosca M Del Tacca 2004 Synergistic cytotoxicity and pharmacogenetics of Gemcitabine and Pemetrexed combinations in pancreatic cancer cell lines Clin Cancer Res 10 2936 2943 10.1158/1078-0432.CCR- 03-0520 (Pubitemid 38619668)
11. AA Adjei C Erlichman JA Sloan, et al. 2000 Phase I and pharmacologic study of sequences of Gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors J Clin Oncol 18 1748 1757 1:CAS:528:DC%2BD3cXjtFajsLk%3D 10764436
12. A Tesei L Ricotti F DePaola D Amadori GL Frassineti W Zoli 2002 In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and Gemcitabine in human colon adenocarcinoma cell lines Clin Cancer Res 8 233 239 1:CAS:528:DC%2BD38XhsVKlsrk%3D 11801564
13. CX Ma P Steen KM Rowland, et al. 2006 A phase II trial of a combination of Pemetrexed and Gemcitabine in patients with metastatic breast cancer: an NCCTG study Ann Oncol 17 226 231 10.1093/annonc/mdj054 1:STN:280: DC%2BD28%2FjvVGluw%3D%3D 16303865 (Pubitemid 43160110)
14. A Kalykaki L Vamvakas S Agelaki, et al. 2006 A dose escalation study of Gemcitabine plus Pemetrexed administered biweekly in patients with solid tumours Oncology 71 197 203 10.1159/000106069 1:CAS:528:DC%2BD2sXpsVejsbg%3D 17641541
15. AZ Dudek T Larson MJ McCleod, et al. 2008 Phase 1/2 dose escalating study of twice-monthly Pemetrexed and Gemcitabine in patients with advanced cancer and non-small cell lung cancer J Thorac Oncol 3 394 399 10.1097/JTO. 0b013e318169cdc4 18379358
16. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
17. S Dent B Zee J Dancey A Hanauske J Wanders E Eisenhauer 2001 Application of a new multinomial phase II stopping rule using response and early progression J Clin Oncol 19 785 791 1:STN:280:DC%2BD3M7kvV2luw%3D%3D 11157032
18. CX Ma S Nair S Thomas, et al. 2005 Randomized phase II trial of three schedules of Pemetrexed and Gemcitabine as front-line therapy for advanced non-small cell lung cancer J Clin Oncol 23 5929 5937 10.1200/JCO.2005.13.953 1:CAS:528:DC%2BD2MXhtVKgtbzK 16135464 (Pubitemid 46300209)